DYSPLASIA DIAGNOSTICS LIMITED

Company Registration Number:
14361617 (England and Wales)

Unaudited abridged accounts for the year ended 30 September 2024

Period of accounts

Start date: 01 October 2023

End date: 30 September 2024

DYSPLASIA DIAGNOSTICS LIMITED

Contents of the Financial Statements

for the Period Ended 30 September 2024

Balance sheet
Notes

DYSPLASIA DIAGNOSTICS LIMITED

Balance sheet

As at 30 September 2024


Notes

2024

2023


£

£
Fixed assets
Tangible assets: 3 340 680
Total fixed assets: 340 680
Current assets
Debtors:   236 6,705
Cash at bank and in hand: 619 263
Total current assets: 855 6,968
Creditors: amounts falling due within one year: 4 (38,174) (34,678)
Net current assets (liabilities): (37,319) (27,710)
Total assets less current liabilities: (36,979) (27,030)
Total net assets (liabilities): (36,979) (27,030)
Capital and reserves
Called up share capital: 100 100
Profit and loss account: (37,079) (27,130)
Shareholders funds: (36,979) (27,030)

The notes form part of these financial statements

DYSPLASIA DIAGNOSTICS LIMITED

Balance sheet statements

For the year ending 30 September 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 16 September 2025
and signed on behalf of the board by:

Name: Denise Williams
Status: Director

The notes form part of these financial statements

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2024

2. Employees

2024 2023
Average number of employees during the period 3 2

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2024

3. Tangible Assets

Total
Cost £
At 01 October 2023 1,020
At 30 September 2024 1,020
Depreciation
At 01 October 2023 340
Charge for year 340
At 30 September 2024 680
Net book value
At 30 September 2024 340
At 30 September 2023 680

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2024

4. Creditors: amounts falling due within one year note

Directors’ advances, credits and guarantees The amounts shown below were owed to the directors at the balance sheet dates. The loans are unsecured, interest free and repayable on demand. During the year the directors confirmed that they would not seek repayment of these loans within 12 months and will provide further finance as required to enable the company to continue as a going concern. Denise Williams: £13,403 Dr. Osagie Izuogu: £24,771 Total: £38,174

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2024

5. Financial commitments

Going concern The company incurred net liabilities of £36,979 as at 30 September 2024. Nevertheless, the directors have assessed the company’s ability to continue as a going concern for a period of at least twelve months from the date of approval of these financial statements. The directors and shareholders have confirmed they will not demand repayment of their loans within this period and will provide such further financial support as is necessary to enable the company to meet its liabilities as they fall due. In preparing cash-flow forecasts, the directors have also considered non-cash cloud compute credits available to the company. As at the date of approval, unused credits of approximately £134,823 remain; these credits are non-transferable, non-refundable, and can only be applied to eligible cloud usage, expiring between June 2026 and May 2027. The credits reduce forecast cash outflows for infrastructure costs but do not give rise to an asset (and are not government grants) and are therefore not recognised in these financial statements; instead, they will reduce cloud expenses when utilised. Having regard to these factors, the directors consider the going-concern basis of preparation to be appropriate.